Safe and Effective Variability-A Criterion for Dose Individualization

被引:69
作者
Holford, Nicholas H. G. [1 ]
Buclin, Thierry [2 ]
机构
[1] Univ Auckland, Dept Pharmacol & Clin Pharmacol, Auckland, New Zealand
[2] Univ Hosp Ctr, Div Clin Pharmacol, Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
population pharmacokinetics; parameter variability; dose individualization; target concentration intervention; safe and effective variability; therapeutic drug monitoring; POPULATION PHARMACOKINETIC MODELS; TARGET CONCENTRATION INTERVENTION; INTEROCCASION;
D O I
10.1097/FTD.0b013e31826aabc3
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: A primary goal of clinical pharmacology is to understand the factors that determine the dose-effect relationship and to use this knowledge to individualize drug dose. Methods: A principle-based criterion is proposed for deciding among alternative individualization methods. Results: Safe and effective variability defines the maximum acceptable population variability in drug concentration around the population average. Conclusions: A decision on whether patient covariates alone are sufficient, or whether therapeutic drug monitoring in combination with target concentration intervention is needed, can be made by comparing the remaining population variability after a particular dosing method with the safe and effective variability.
引用
收藏
页码:565 / 568
页数:4
相关论文
共 17 条